AI Article Synopsis
- - Central dopaminergic neurotransmission issues are linked to schizophrenia, and the cholinergic agonist xanomeline shows promise as an antipsychotic in clinical studies.
- - The M(4) muscarinic cholinergic receptor subtype is crucial for the effects of xanomeline, particularly as it interacts with D(1) dopamine receptors to regulate dopamine-related behaviors.
- - Experiments with mutant mice lacking M(4) receptors in D(1) cells reveal that these receptors are essential for xanomeline's antipsychotic-like effects, suggesting they could be a target for future treatments for psychosis.
Article Abstract
Disturbances in central dopaminergic neurotransmission are believed to be centrally involved in the pathogenesis of schizophrenia. Central dopaminergic and cholinergic systems interact and the cholinergic muscarinic agonist xanomeline has shown antipsychotic effects in clinical studies. Preclinical studies indicate that the M(4) muscarinic cholinergic receptor subtype (mAChR) modulates the activity of the dopaminergic system and that this specific mAChR subtype is involved in mediating the antipsychotic-like effects of xanomeline. A specific neuronal subpopulation that expresses M(4) mAChRs together with D(1) dopamine receptors seems to be especially important in modulating dopamine-dependent behaviors. Using mutant mice that lack the M(4) mAChR only in D(1) dopamine receptor-expressing cells (D1-M4-KO), we investigated the role of this neuronal population in the antipsychotic-like effects of xanomeline in amphetamine-induced hyperactivity and apomorphine-induced climbing. Interestingly, the antipsychotic-like effects of xanomeline in the two models were almost completely abolished in D1-M4-KO mice, suggesting that M(4) mAChRs colocalized with D(1) dopamine receptors are centrally involved in mediating the antipsychotic-like effects of xanomeline. This is consistent with the hypothesis that activation of the M(4) mAChR represents a potential target for the future medical treatment of psychosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6632952 | PMC |
| http://dx.doi.org/10.1523/JNEUROSCI.0370-11.2011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mapping of c-Fos Expression in Rat Brain Sub/Regions Following Chronic Social Isolation: Effective Treatments of Olanzapine, Clozapine or Fluoxetine.
Pharmaceuticals (Basel)
November 2024
Department of Molecular Biology and Endocrinology, "VINČA" Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, 11000 Belgrade, Serbia.
The c-Fos as a marker of cell activation is used to identify brain regions involved in stimuli processing. This review summarizes a pattern of c-Fos immunoreactivity and the overlapping brain sub/regions which may provide hints for the identification of neural circuits that underlie depressive- and anxiety-like behaviors of adult male rats following three and six weeks of chronic social isolation (CSIS), relative to controls, as well as the antipsychotic-like effects of olanzapine (Olz), and clozapine (Clz), and the antidepressant-like effect of fluoxetine (Flx) in CSIS relative to CSIS alone. Additionally, drug-treated controls relative to control rats were also characterized.
View Article and Find Full Text PDFAntipsychotic Activity of Ethanolic Extracts of Crinum asiaticum and Crinum defixum in Animal Models.
Zhongguo Ying Yong Sheng Li Xue Za Zhi
October 2024
Sri Jaydev College of Pharmaceutical Sciences, Naharkanta, Bhubaneswar, Odisha-752101, India.
The current study examined the antipsychotic properties of ethanolic extracts of Crinum asiaticum (EECA) and Crinum defixum (EECD). The effects of the extracts on rodents' ketamine-induced hyperactivity, amphetamine-induced stereotypy, forced swim test, conditioned avoidance response, and catalepsy were assessed. According to the findings, EECA and EECD both significantly outperformed typical antipsychotic medications in antipsychotic-like behaviours across a variety of behavioural paradigms.
View Article and Find Full Text PDFCannabidiol attenuates prepulse inhibition disruption by facilitating TRPV1 and 5-HT1A receptor-mediated neurotransmission.
Pharmacol Biochem Behav
December 2024
Department of Neurosciences and Behavioral Sciences, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil; Department of Physiology, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil; Department of Basic and Oral Biology, School of Dentistry of Ribeirão Preto, University of Sao Paulo, Ribeirao Preto, SP, Brazil.
Individuals with schizophrenia (SCZ) often present sensorimotor gating impairments that can be investigated by the prepulse inhibition test (PPI). PPI disruption can be mimicked experimentally with psychostimulants such as amphetamine and attenuated/reversed by antipsychotics. Cannabidiol (CBD), the main non-psychotomimetic component of the Cannabis sativa plant, produces antipsychotic-like effects in clinical and preclinical studies.
View Article and Find Full Text PDFAlphaFold accelerated discovery of psychotropic agonists targeting the trace amine-associated receptor 1.
Sci Adv
August 2024
Neuro Svenningsson, Department of Clinical Neuroscience, Karolinska Institute, SE-171 76 Stockholm, Sweden.
Artificial intelligence is revolutionizing protein structure prediction, providing unprecedented opportunities for drug design. To assess the potential impact on ligand discovery, we compared virtual screens using protein structures generated by the AlphaFold machine learning method and traditional homology modeling. More than 16 million compounds were docked to models of the trace amine-associated receptor 1 (TAAR1), a G protein-coupled receptor of unknown structure and target for treating neuropsychiatric disorders.
View Article and Find Full Text PDFmGluR5 positive allosteric modulation prevents MK-801 induced increases in extracellular glutamate in the rat medial prefrontal cortex.
Neuroscience
September 2024
Department of Psychology, Arizona State University, 950 S. McAllister Ave., Tempe, AZ 85281, United States.
Potentiation of metabotropic glutamate receptor subtype 5 (mGluR5) function produces antipsychotic-like and pro-cognitive effects in animal models of schizophrenia and can reverse cognitive deficits induced by N-methyl-D-aspartate type glutamate receptor (NMDAR) antagonists. However, it is currently unknown if mGluR5 positive allosteric modulators (PAMs) can modulate NMDAR antagonist-induced alterations in extracellular glutamate levels in regions underlying these cognitive and behavioral effects, such as the medial prefrontal cortex (mPFC). We therefore assessed the ability of the mGluR5 PAM, 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl) benzamide (CDPPB), to reduce elevated extracellular glutamate levels induced by the NMDAR antagonist, dizocilpine (MK-801), in the mPFC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!